Use of colistin with rifampicin, trimethoprim-sulfamethoxazole and teicoplanin in Acinetobacter mouse infection model

Infections with multidrug-resistant Gram-negative bacteria such as are major cause of morbidity and mortality. Colistin is used commonly to treat these infections. In this study, we evaluated the efficacy of different colistin combinations in a infection mouse model. An mouse infection model was dev...

Full description

Saved in:

Bibliographic Details
Published in:	Future microbiology Vol. 17; no. 9; pp. 665 - 671
Main Authors:	Yesil, Cihan, Yalcin, Ata N, Ogunc, Dilara, Ongut, Gozde, Ozhak, Betül, Colak, Dilek, Er, Halil, Sarıtas, Zubeyde E
Format:	Journal Article
Language:	English
Published:	England 01-06-2022
Subjects:	Acinetobacter baumannii Acinetobacter Infections - microbiology Animals Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Colistin - pharmacology Colistin - therapeutic use Disease Models, Animal Mice Rifampin - pharmacology Rifampin - therapeutic use Teicoplanin - pharmacology Teicoplanin - therapeutic use Trimethoprim, Sulfamethoxazole Drug Combination - pharmacology Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use antibiotherapy rifampicin Acinetobacter baumannii trimethoprim-sulfamethoxazole monotherapy combination therapy colistin
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Infections with multidrug-resistant Gram-negative bacteria such as are major cause of morbidity and mortality. Colistin is used commonly to treat these infections. In this study, we evaluated the efficacy of different colistin combinations in a infection mouse model. An mouse infection model was developed in 150 experimental animals. Treatment groups were as follows: colistin, colistin + rifampicin, colistin + trimethoprim/sulfamethoxazole, colistin + teicoplanin and a control group. The outcome was bacterial burden in the lung and liver tissues. The treatment groups were subdivided into 24-, 48- and 72-h groups. Colistin and combinations reduce the burden significantly in lung and liver tissues compared with the control group. Compared with colistin alone colistin + rifampicin and colistin + TMP-SMX provided significantly better reduction in the bacterial burden. These results may suggest that rifampicin and TMP-SMX combination with colistin may have a potential role in the treatment of infections.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1746-0913 1746-0921
DOI:	10.2217/fmb-2021-0216